[
  {
    "ts": null,
    "headline": "Johnson & Johnson : MedTech Presents 3 Month Data from Omny IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting",
    "summary": "Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting Omny-IRE data demonstrated the investigational...",
    "url": "https://finnhub.io/api/news?id=98dec1f1ee56806f255c98103b91a1b7a9d0202de74de107eeeaa702b2304a3e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745599479,
      "headline": "Johnson & Johnson : MedTech Presents 3 Month Data from Omny IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting",
      "id": 134095916,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting Omny-IRE data demonstrated the investigational...",
      "url": "https://finnhub.io/api/news?id=98dec1f1ee56806f255c98103b91a1b7a9d0202de74de107eeeaa702b2304a3e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Q1 Earnings Reinforce Positive Momentum",
    "summary": "AbbVie Inc.'s strong fundamentals, healthy dividends, and acceptable forward P/Es for the medium term make a case. Read more on ABBV earnings update.",
    "url": "https://finnhub.io/api/news?id=2d5e4b04a5ac5e407c51416adbb69373ff8835c4fe5385795837a15bc353363a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745596804,
      "headline": "AbbVie: Q1 Earnings Reinforce Positive Momentum",
      "id": 134095648,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc.'s strong fundamentals, healthy dividends, and acceptable forward P/Es for the medium term make a case. Read more on ABBV earnings update.",
      "url": "https://finnhub.io/api/news?id=2d5e4b04a5ac5e407c51416adbb69373ff8835c4fe5385795837a15bc353363a"
    }
  },
  {
    "ts": null,
    "headline": "Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing",
    "summary": "Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing",
    "url": "https://finnhub.io/api/news?id=5d8eac37b3293774beb7514478c3fc4cb9982fbb645b06af6eae409526b9565f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745591400,
      "headline": "Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing",
      "id": 134127344,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Another drugmaker says tax reform, not tariffs, would drive U.S. manufacturing",
      "url": "https://finnhub.io/api/news?id=5d8eac37b3293774beb7514478c3fc4cb9982fbb645b06af6eae409526b9565f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Soared as Markets Favored Defensive Sector",
    "summary": "Mar Vista Investment Partners, LLC, an investment management company, released the “Mar Vista U.S. Quality Select Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. US stocks suffered their worst quarter in three years, with the steepest losses since 2022, due to tariff concerns and economic stagnation fears. In the […]",
    "url": "https://finnhub.io/api/news?id=5623979c314ae247a798c1b33d233586132288ffa4fbdf67671b5beafe2ac465",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745580590,
      "headline": "Johnson & Johnson (JNJ) Soared as Markets Favored Defensive Sector",
      "id": 134087629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Mar Vista Investment Partners, LLC, an investment management company, released the “Mar Vista U.S. Quality Select Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. US stocks suffered their worst quarter in three years, with the steepest losses since 2022, due to tariff concerns and economic stagnation fears. In the […]",
      "url": "https://finnhub.io/api/news?id=5623979c314ae247a798c1b33d233586132288ffa4fbdf67671b5beafe2ac465"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 117-point drop led by losses in Merck, Verizon shares",
    "summary": "Dow's 117-point drop led by losses in Merck, Verizon shares",
    "url": "https://finnhub.io/api/news?id=93d6da8a0ba11f5d654b4c9f828fd83ef2aed0a9743c1209b2f0820595f38d09",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745574360,
      "headline": "Dow's 117-point drop led by losses in Merck, Verizon shares",
      "id": 134127254,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Dow's 117-point drop led by losses in Merck, Verizon shares",
      "url": "https://finnhub.io/api/news?id=93d6da8a0ba11f5d654b4c9f828fd83ef2aed0a9743c1209b2f0820595f38d09"
    }
  },
  {
    "ts": null,
    "headline": "Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say",
    "summary": "Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say",
    "url": "https://finnhub.io/api/news?id=f4985392d235f928ad3b7baff9cd9af5068d6e7db3af90bcf5231a60c634036d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745574000,
      "headline": "Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say",
      "id": 134146888,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say",
      "url": "https://finnhub.io/api/news?id=f4985392d235f928ad3b7baff9cd9af5068d6e7db3af90bcf5231a60c634036d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?",
    "summary": "Biogenâs lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.",
    "url": "https://finnhub.io/api/news?id=ef3adb4bcd126997d1f1592527ecb2afc521115bd3cda32b4212595c2984fefe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745572551,
      "headline": "Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?",
      "id": 134077371,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165724853/image_2165724853.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Biogenâs lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.",
      "url": "https://finnhub.io/api/news?id=ef3adb4bcd126997d1f1592527ecb2afc521115bd3cda32b4212595c2984fefe"
    }
  },
  {
    "ts": null,
    "headline": "US business lobby in China: Some pharma firms reporting tariff exemptions",
    "summary": "SHANGHAI -Pharmaceutical companies in China are reporting that they have been able to import some drugs over the past week with tariff exemptions, the Beijing-based American Chamber of Commerce said...",
    "url": "https://finnhub.io/api/news?id=6ebbdf327bce0c1aaaf50a9470ca15d0ce6d4d10545f2b3ce9e10a5308eeb8f4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745570458,
      "headline": "US business lobby in China: Some pharma firms reporting tariff exemptions",
      "id": 134074791,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "SHANGHAI -Pharmaceutical companies in China are reporting that they have been able to import some drugs over the past week with tariff exemptions, the Beijing-based American Chamber of Commerce said...",
      "url": "https://finnhub.io/api/news?id=6ebbdf327bce0c1aaaf50a9470ca15d0ce6d4d10545f2b3ce9e10a5308eeb8f4"
    }
  }
]